ReviewDigestive diseases (Basel, Switzerland)2019
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
Review in Digestive diseases (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Can ammonia scavenging treat MASLD? Evaluating the evidence for L-ornithine L-aspartate-A systematic review.European journal of clinical investigation · 2026Pooled it
- Safety assessment of L-ornithine oral intake in healthy subjects: a systematic review.Amino acids · 2025Pooled it
- Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.Metabolic brain disease · 2020Pooled it
- "L-Ornithine Liposomal Nanoparticles Targeting the Proline Cycle: A Mechanistic Perspective for Ammonia-Driven Hepatic Encephalopathy".Cell biochemistry and biophysics · 2026Review
- Effects of dietary L-Ornithine L-Aspartate supplementation on growth performance, immune function, and intestinal health in lipopolysaccharide-challenged broilers.Poultry science · 2026Article
- Urea cycle dysregulation and arginine pathways in the pathogenesis of NAFLD and NASH (Review).International journal of molecular medicine · 2026Review
- Dietary L-Ornithine L-Aspartate Alleviates Ammonia Load and Improves Hepatic Health in Largemouth Bass (Animals : an open access journal from MDPI · 2026Article
- L-Ornithine-L-aspartate enhances growth performance and nitrogen metabolism via modulation of intestinal amino acid transporters and microbiota in broilers.Journal of animal science and biotechnology · 2026Article
- Research Progress on the Physiological Functions of Aspartic Acid and Its Applications in Animal Production.Animals : an open access journal from MDPI · 2026Review
- Beyond Organ Boundaries: Molecular Mechanisms of Hepatic Encephalopathy and Parkinson's Disease from the Perspective of the Gut-Liver-Brain Axis.Research (Washington, D.C.) · 2026Review
- Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future.Diabetology international · 2025Article
- Analysis and mining of L-ornithine L-aspartate adverse events based on FAERS database.Scientific reports · 2025Article
- Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Nutrients · 2024Review
- Identification of Primary Metabolite Profiles Reveals Quality Characteristics ofCurrent issues in molecular biology · 2024Article
- Redefining the Role of Ornithine Aspartate and Vitamin E in Metabolic-Dysfunction-Associated Steatotic Liver Disease through Its Biochemical Properties.International journal of molecular sciences · 2024Article
- Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease.World journal of hepatology · 2024Article
- Liver Diseases: Science, Fiction and the Foreseeable Future.Journal of personalized medicine · 2024Article
- l-Ornithine-l-Aspartate (LOLA) Normalizes Metabolic Parameters in Models of Steatosis, Insulin Resistance and Metabolic Syndrome.Pharmaceutics · 2024Article
- Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.Pharmacological reports : PR · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited. SUMMARY: L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6-9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. A preliminary report described improvements of hepatic microcirculation in patients with non-alcoholic steatohepatitis (NASH) following treatment with LOLA. Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve, in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties. Key Messages: (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. (2) Mechanisms other than LOLA's ammonia-lowering action have been postulated. (3) Further assessments in the clinical setting are now required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.